A serological assay to detect SARS-CoV-2 seroconversion in humans

By F. Amanat, D. Stadlbauer, Shirin Strohmeier, T. Nguyen, Veronika Chromikova, Meagan McMahon, Kaijun Jiang, G. Arunkumar, D. Jurczyszak, J. Polanco and 20 more. Nature Medicine, 2020

1,228 citations recorded by the source corpus.

Here, we describe a serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters. This assay does not require the handling of infectious virus, can be adjusted to detect different antibody types in serum and plasma and is amenable to scaling. Serological assays are of critical importance to help define previous exposure to SARS-CoV-2 in populations, identify highly reactive human donors for convalescent plasma therapy and investigate correlates of protection. Development of an enzyme-linked immunosorbent assay to detect antibodies to the SARS-CoV-2 spike protein in human sera and plasma.

Subfields: Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/7f3597d471d47f77a2112f5e72b08682ee62f3c6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. D. Veesler
2. M. A. Tortorici
3. Alessandro Sette
4. Shane Crotty
5. F. Krammer
6. Jesse D. Bloom

Citations in the corpus

• Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays (2020, background): “However, while there are now well-characterized and high-throughput methods (such as ELISA assays) to measure total antibody binding to SARS-CoV-2 or some of its key constituent proteins [2,6,26], quantifying neutralizing antibody activity is more difficult.”
• Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection (2021, methodology): “SARS-CoV-2 ELISAs were performed as previously described (2, 5, 82).”
• Adaptive immunity to SARS-CoV-2 and COVID-19 (2021, neutral): “As a result, cross-reactive circulating anti-Spike crossneutralizing antibodies are rare (Amanat et al., 2020; Okba et al., 2020; Suthar et al., 2020; Tan et al., 2020b; Wec et al., 2020), as are cross-reactive Spike memory B cells (see above).”
• Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19 (2020, neutral): “In persons with COVID-19, the magnitude and durability of antibody responses are greater in those with more severe disease (Ju et al., 2020; Amanat et al., 2020) but are often of low magnitude (Robbiani et al.”
• Sex differences in immune responses that underlie COVID-19 disease outcomes (2020, neutral): “ELISAs were performed as previously described 20 .”